Saturday 17 October 2026
Export VCEL’s income statement to Excel — free account
Vericel Corporation
VCEL Healthcare Biotechnology
Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024. In the quarter to June 2026, revenue grew 22.5%, EPS grew 500.0% and free cash flow grew 17,503.7%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
40.13
0.89
−2.17%
Follow VCEL
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 441.14 | 0.00 | 0.00 | 0.00 | 274.55 | 112.53 |
Piotroski F-Score |
3 | 4 | 5 | 4 | 5 | 6 | 3 | 5 | 6 | 7 |
P/S ratio |
1.23 | 3.08 | 7.71 | 6.52 | 11.25 | 11.69 | 7.21 | 8.40 | 11.31 | 6.56 |
Altman Z-Score |
(7.56) | (4.76) | 22.82 | 8.73 | 10.42 | 13.95 | 8.23 | 7.41 | 11.20 | 8.21 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 93.43 | 86.45 | 117.37 | 212.87 | 0.00 | 73.25 |
Altman Z″-Score (non-manufacturers) |
(20.32) | (18.16) | 1.58 | (1.85) | (0.68) | 0.66 | 0.89 | 0.98 | 1.75 | 3.10 |
Beneish M-Score |
(2.53) | (2.79) | (2.25) | (2.25) | (2.52) | (3.15) | (2.99) | (2.53) | (2.86) | (2.53) |
P/Operating CF |
(7.19) | 235.96 | 268.18 | 244.04 | 123.17 | 173.10 | 169.80 | 164.58 | 120.59 | 120.74 |
P/B ratio |
0.00 | 8.73 | 6.85 | 6.92 | 10.40 | 10.71 | 6.16 | 7.35 | 9.19 | 5.11 |
Price to Tangible BV |
0.00 | 9.92 | 7.04 | 7.09 | 10.62 | 10.89 | 6.41 | 7.58 | 9.39 | 5.19 |
EV/Sales |
0.99 | 2.93 | 6.98 | 6.08 | 10.77 | 11.14 | 6.58 | 7.85 | 10.85 | 6.13 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 263.73 | 0.00 | 0.00 | 0.00 | 268.53 | 74.82 |
EV/Operating CF |
(2.72) | (14.20) | (1,540.21) | (99.72) | 76.14 | 59.93 | 61.18 | 43.89 | 44.23 | 32.61 |
EV/FCF |
(2.54) | (12.74) | (205.36) | (73.10) | 89.52 | 82.38 | 107.24 | 198.75 | (442.74) | 68.39 |
Quick Ratio |
3.12 | 3.45 | 7.19 | 5.15 | 4.91 | 5.41 | 4.43 | 4.06 | 3.74 | 4.52 |
Current Ratio |
3.48 | 3.86 | 7.62 | 5.64 | 5.50 | 6.08 | 4.99 | 4.49 | 4.23 | 5.03 |
Net Debt/EBITDA |
0.88 | 0.72 | 29.51 | 6.89 | (14.94) | 26.24 | 9.28 | 52.17 | (13.23) | (6.08) |
Debt/Assets |
20.78% | 31.58% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.41 | 0.76 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
1.31 | 1.24 | 1.05 | 0.87 | 0.69 | 0.70 | 0.64 | 0.63 | 0.60 | 0.60 |
Operating CF/Net income |
1.02 | 0.76 | 0.05 | 0.74 | 6.14 | (3.89) | (1.06) | (11.10) | 5.61 | 3.14 |
Capex/Depreciation |
(0.31) | (0.94) | (2.44) | (2.31) | (0.97) | (2.02) | (1.82) | (6.84) | (12.64) | (2.35) |
Interest Coverage |
(61.29) | (13.54) | (2.26) | (1,406.37) | 395.33 | (1,963.50) | (46.61) | (10.77) | 7.36 | 17.53 |
| 118.26% | (390.25%) | (13.04%) | (9.06%) | 2.33% | (4.90%) | (9.21%) | (1.52%) | 4.00% | 5.11% | |
| (47.20%) | (33.51%) | (9.39%) | (7.11%) | 1.60% | (3.33%) | (6.47%) | (1.02%) | 2.64% | 3.59% | |
ROIC |
(101.70%) | (72.51%) | (12.65%) | (17.00%) | 2.54% | (7.32%) | (14.66%) | (4.10%) | 1.71% | 3.18% |
Return on Tangible Assets |
(54.74%) | (41.67%) | (7.83%) | (9.76%) | 2.63% | (5.13%) | (10.11%) | (1.58%) | 3.90% | 5.39% |
Average Days of Receivables |
114.72 | 104.32 | 94.22 | 99.63 | 101.42 | 87.49 | 103.35 | 107.84 | 94.43 | 111.82 |
Research and Development Expense of Revenue |
28.12% | 20.25% | 14.97% | 25.79% | 10.48% | 10.43% | 12.13% | 10.65% | 10.45% | 9.98% |
Selling, General and Administrative Expense of Revenue |
50.36% | 55.71% | 53.94% | 51.88% | 55.43% | 62.49% | 65.04% | 61.26% | 60.19% | 60.45% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.02 | 0.01 | 0.01 |
Share Based Compensation of Revenue |
4.60% | 4.19% | 7.95% | 11.18% | 11.15% | 21.98% | 22.62% | 16.37% | 15.38% | 14.03% |
Graham Net Nets |
0.31 | 0.09 | 0.14 | 0.09 | 0.04 | 0.05 | 0.09 | 0.05 | 0.03 | 0.06 |
Graham Number |
3.68 | 0.00 | 0.00 | 0.00 | 2.16 | 0.00 | 0.00 | 0.00 | 5.19 | 7.12 |
Earnings Yield |
(35.02%) | (8.98%) | (1.32%) | (1.32%) | 0.23% | (0.41%) | (1.39%) | (0.23%) | 0.36% | 0.89% |
Free Cash Flow Yield |
(31.82%) | (7.47%) | (0.44%) | (1.27%) | 1.07% | 1.16% | 0.85% | 0.47% | (0.22%) | 1.37% |
Revenue per Share |
2.36 | 1.92 | 2.26 | 2.67 | 2.75 | 3.36 | 3.49 | 4.15 | 4.86 | 5.49 |
Operating CF per Share |
(0.86) | (0.40) | (0.01) | (0.16) | 0.39 | 0.62 | 0.38 | 0.74 | 1.19 | 1.03 |
Capex per Share |
(0.06) | (0.05) | (0.07) | (0.06) | (0.06) | (0.17) | (0.16) | (0.58) | (1.31) | (0.54) |
Free Cash Flow per Share |
(0.92) | (0.44) | (0.08) | (0.22) | 0.33 | 0.45 | 0.21 | 0.16 | (0.12) | 0.49 |
Cash per Share |
1.00 | 0.81 | 2.06 | 1.58 | 1.68 | 2.23 | 2.54 | 2.68 | 2.59 | 2.73 |
Shareholders Equity per Share |
1.07 | 0.68 | 2.54 | 2.51 | 2.97 | 3.67 | 4.08 | 4.75 | 5.98 | 7.04 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.07 | 0.68 | 2.54 | 2.51 | 2.97 | 3.67 | 4.08 | 4.75 | 5.98 | 7.04 |
Free Cash Flow |
(21.31) | (14.69) | (3.09) | (9.80) | 14.95 | 21.13 | 10.09 | 7.80 | (5.81) | 24.75 |
Working Capital |
31.87 | 37.42 | 97.99 | 91.86 | 101.08 | 132.41 | 149.40 | 159.88 | 162.49 | 198.29 |
Capital Expenditures |
(1.41) | (1.51) | (2.68) | (2.62) | (2.63) | (7.91) | (7.60) | (27.51) | (63.97) | (27.16) |
Net Current Asset Value |
20.83 | 18.47 | 96.33 | 69.51 | 52.21 | 85.22 | 106.14 | 77.93 | 72.02 | 114.11 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 564.04 | 0.00 | 0.00 | 0.00 | 569.33 | 153.25 |
Capex to Sales |
0.03 | 0.02 | 0.03 | 0.02 | 0.02 | 0.05 | 0.05 | 0.14 | 0.27 | 0.10 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 588.71 | 0.00 | 0.00 | 0.00 | 593.55 | 164.14 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.17 | 0.40 | 0.19 | 0.16 | 0.35 | 0.29 | 0.26 | 0.10 | 0.05 | 0.11 |
Cash ROIC |
(36.87%) | (22.05%) | (1.67%) | (5.42%) | 7.11% | 7.71% | 3.24% | 2.21% | (1.39%) | 5.03% |
Accounts Receivable Turnover |
3.88 | 3.62 | 4.36 | 4.24 | 3.73 | 4.34 | 3.91 | 3.77 | 3.96 | 3.78 |
Accounts Payable Turnover |
4.01 | 5.02 | 5.08 | 5.59 | 6.10 | 6.36 | 4.21 | 3.15 | 2.82 | 3.56 |
Inventory Turnover |
11.63 | 8.34 | 8.75 | 7.24 | 4.94 | 4.41 | 3.72 | 4.26 | 4.28 | 4.05 |
Average Days of Payables |
84.26 | 66.76 | 80.67 | 61.64 | 61.72 | 65.61 | 113.22 | 131.69 | 133.68 | 81.76 |
Days of Inventory on Hand |
44.98 | 45.61 | 40.38 | 66.22 | 85.48 | 97.37 | 106.91 | 77.12 | 97.38 | 90.71 |
Average Receivables |
14.01 | 17.68 | 20.86 | 27.81 | 33.34 | 35.97 | 41.99 | 52.45 | 59.87 | 73.00 |
Average Payables |
7.06 | 6.04 | 6.33 | 6.73 | 6.55 | 7.89 | 12.97 | 19.64 | 23.10 | 19.84 |
Average Inventory |
2.43 | 3.64 | 3.68 | 5.19 | 8.09 | 11.37 | 14.68 | 14.54 | 15.23 | 17.47 |
Average Assets |
41.45 | 51.59 | 86.63 | 135.96 | 179.42 | 224.66 | 258.35 | 313.33 | 393.19 | 460.35 |
Average Common Equity |
(16.54) | 4.43 | 62.39 | 106.66 | 122.68 | 152.36 | 181.37 | 209.11 | 258.96 | 323.30 |
Columns are period end dates